| Tipo : |
Periódico |
| Enlace : |
http://www.ijpc.com/Abstracts/Abstract.cfm?ABS=284 |
|
| Los equipos de investigación : |
Houston - M.D.Anderson Cancer Center |
| Autores : |
Zhang YP, Trissel LA, Fox JL. |
| Título : |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions. |
| Número : |
Int J Pharm Compound ; 4: 69-71. 2000 |
|
| Nivel de evidencia : |
|
| La estabilidad física : |
|
| Estabilidad química : |
|
| Otros métodos : |
|
| Comentarios : |
|
Lista de la molécula
 Naratriptan Hydrochloride
|
 |
 |
 |
 |
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
23°C |
 |
| 7 |
 |
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
23°C |
|
| 7 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
